TABLE 3

Steady-state pharmacokinetic parameter estimates for antituberculosis drugs by HIV coinfection status

Drug and parameterValue for groupP value
All (n = 113)TB (n = 54)TB/HIV (n = 59)
Isoniazid
    Cmax, μg/ml5.75 (4.27–7.47)5.85 (4.27–7.47)5.32 (4.03–7.61)0.794
    Tmax, h1.05 (1.00–1.22)1.07 (1.00–1.45)1.02 (1.00–1.15)0.015
    AUC0–8, μg · h/ml19.73 (13.24–26.43)21.15 (16.48–25.92)18.37 (12.20–26.90)0.231
    Normalized Vz/F, liters/kg1.51 (1.20–1.90)1.55 (1.27–1.84)1.47 (1.15–2.00)0.957
    Normalized CL/F, liters/h/kg0.47 (0.33–0.71)0.44 (0.32–0.70)0.50 (0.33–0.78)0.405
Rifampin
    Cmax, μg/ml6.39 (4.92–8.77)7.65 (5.20–9.10)5.83 (3.71–8.26)0.025
    Tmax, h2.00 (1.07–2.17)2.01 (1.13–2.28)1.83 (1.02–2.08)0.090
    AUC0–8, μg · h/ml27.25 (20.62–36.32)30.49 (21.93–38.44)24.88 (15.95–35.27)0.030
    Normalized Vz/F, liters/kg1.46 (1.11–2.10)1.37 (1.08–2.05)1.63 (1.21–2.22)0.142
    Normalized CL/F, liters/h/kg0.50 (0.37–0.74)0. 45 (0.35–0.66)0.53 (0.41–0.86)0.044
Pyrazinamide (n = 110)
    Cmax, μg/ml26.05 (21.70–35.10)26.90 (23.15–34.60)24.60 (20.60–36.50)0.259
    Tmax, h1.16 (1.00–2.07)1.93 (1.05–2.10)1.04 (1.00–1.77)0.006
    AUC0–8, μg · h/ml140.50 (114.18–186.19)151.04 (124.64–188.81)126.53 (105.41–182.34)0.034
    Normalized Vz/F, liters/kg0.87 (0.74–1.08)0.88 (0.75–1.08)0.85 (0.73–1.19)0.661
    Normalized CL/F, liters/h/kg0.11 (0.08–0.14)0.10 (0.07–0.12)0.12 (0.09–0.16)0.010
Ethambutol (n = 110)
    Cmax, μg/ml1.67 (0.87–2.68)2.28 (1.48–3.05)1.33 (0.75–1.92)<0.001
    Tmax, h2.04 (1.70–2.23)2.03 (1.40–2.20)2.05 (1.83–2.33)0.641
    AUC0–8, μg · h/ml6.17 (3.71–9.15)7.57 (5.16–10.68)4.76 (2.98–6.76)<0.001
    Normalized Vz/F, liters/kg8.98 (6.68–18.09)8.12 (5.97–11.04)11.25 (7.70–18.72)0.008
    Normalized CL/F, liters/h/kg2.38 (1.76–3.38)1.96 (1.51–2.73)2.95 (2.20–3.81)0.001